6 minute read
May 13, 2022

Lenrispodun: a Phosphodiesterase (PDE) Type 1 (PDE1) Inhibitor


oral, CNS-penetrant, picomolar PDE1 inhibitor Ph. I/II in neurology and heart failure from literature starting point, LBDD and SBDD Neuropsychopharmacology Intra-Cellular Therapies, New York, NY

Drug Hunter Team

Context. Lenrispodun (Intra-Cellular Therapies) is a phosphodiesterase (PDE) type 1 (PDE1) inhibitor being developed for CNS and non-CNS disorders, including heart failure, and cancer. Studies to identify PDE inhibitors date back at least 30 years, and at least 10 drugs have been approved targeting other PDE proteins (spearheaded by the PDE5 [...]



Other molecules you may be interested in